Acumen Pharmaceuticals, Inc. (ABOS) Stock

Acumen Pharmaceuticals, Inc. (ABOS) is a Healthcare stock trading at $2.27 (as of 2026-06-18), with a market capitalization of $165.40M and a trailing P/E of -1.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer’s disease. Its work centers on ACU193, a humanized monoclonal antibody intended to target soluble amyloid-beta oligomers and currently in Phase I clinical development.

Valuation — source: SEC EDGAR (first-party)
Price	$2.27
Market Cap	$165.40M
P/E Ratio	-1.2
EV / EBITDA	-1.2
Price / Book	1.86
Price / Sales	26.91
DCF Value (model)	$-26.94
DCF Upside vs Price	-1286.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$7.45M
Net Margin	-1629.3%
Return on Equity	-129.5%
Debt / Equity	0.35
Current Ratio	4.55
Revenue Growth (YoY)	-56.9%
EPS Growth (YoY)	-31.2%
FCF Growth (YoY)	-29.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-5.58 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-105.8%
vs Industry	-107.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($49.54M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daniel J. O'Connell
Employees	61
Country	US
IPO Date	2022-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.